<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">docru</journal-id><journal-title-group><journal-title xml:lang="ru">Доктор.Ру</journal-title><trans-title-group xml:lang="en"><trans-title>Title</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1727-2378</issn><issn pub-type="epub">2713-2994</issn><publisher><publisher-name>ООО "ГК "РУСМЕДИКАЛ"</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.31550/1727-2378-2024-23-6-46-51</article-id><article-id custom-type="elpub" pub-id-type="custom">docru-304</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL PAPERS</subject></subj-group></article-categories><title-group><article-title>Санаторная реабилитация детей школьного возраста с постковидным астеническим синдромом</article-title><trans-title-group xml:lang="en"><trans-title>Sanatorium Rehabilitation of post-COVID Asthenic Syndrome in School-Age Children</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0008-0566-3010</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Виноградов</surname><given-names>Е. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Vinogradov</surname><given-names>E. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Виноградов Евгений Игоревич — аспирант кафедры неврологии и медицинской генетики ФГБОУ ВО ПГМУ им. академика Е.А. Вагнера Минздрава России.</p><p>614000, Пермь, ул. Петропавловская, д. 26</p></bio><bio xml:lang="en"><p>26 Petopavlovskaya Str., Perm, 614000</p></bio><email xlink:type="simple">i@evgenyi228.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2317-7808</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Селянина</surname><given-names>Н. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Selyanina</surname><given-names>N. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Селянина Наталия Васильевна — профессор кафедры неврологии и медицинской генетики ФГБОУ ВО ПГМУ им. академика Е.А. Вагнера Минздрава России, д. м. н., профессор.</p><p>614000, Пермь, ул. Петропавловская, д. 26</p></bio><bio xml:lang="en"><p>26 Petopavlovskaya Str., Perm, 614000</p></bio><email xlink:type="simple">nselyanina@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Злотникова</surname><given-names>В. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Zlotnikova</surname><given-names>V. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Злотникова Вера Геннадьевна — заведующая педиатрическим отделением детского пульмонологического санатория «Светлана» ГБУЗ ПК «КДКБ».</p><p>614109, Пермь, ул. Танцорова, д. 14</p></bio><bio xml:lang="en"><p>14 Tantzorova Str., Perm, 614109</p></bio><email xlink:type="simple">verazlotnikova@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0498-4900</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сумливая</surname><given-names>О. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Sumlivaya</surname><given-names>O. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Сумливая Ольга Николаевна — д. м. н., доцент, профессор кафедры инфекционных болезней ФГБОУ ВО ПГМУ им. академика Е.А. Вагнера Минздрава России.</p><p>614000, Пермь, ул. Петропавловская, д. 26</p></bio><bio xml:lang="en"><p>26 Petopavlovskaya Str., Perm, 614000</p></bio><email xlink:type="simple">son-2005@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО «Пермский государственный медицинский университет имени академика Е.А. Вагнера» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Perm State Medical University named after Academician E.A. Wagner</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ГБУЗ ПК «Краевая детская клиническая больница»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Regional Children’s Clinical Hospital</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>20</day><month>02</month><year>2025</year></pub-date><volume>23</volume><issue>6</issue><issue-title>ПЕДИАТРИЯ</issue-title><fpage>46</fpage><lpage>51</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Виноградов Е.И., Селянина Н.В., Злотникова В.Г., Сумливая О.Н., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Виноградов Е.И., Селянина Н.В., Злотникова В.Г., Сумливая О.Н.</copyright-holder><copyright-holder xml:lang="en">Vinogradov E.I., Selyanina N.V., Zlotnikova V.G., Sumlivaya O.N.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://docru.elpub.ru/jour/article/view/304">https://docru.elpub.ru/jour/article/view/304</self-uri><abstract><sec><title>Цель исследования</title><p>Цель исследования. Изучение влияния санаторных реабилитационных факторов на выраженность астенических проявлений постковидного синдрома у детей школьного возраста.</p></sec><sec><title>Дизайн</title><p>Дизайн. Нерандомизированное контролируемое исследование.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Обследованы 60 детей в возрасте 8–13 лет с астеническими проявлениями постковидного синдрома, 20 здоровых детей выступили в качестве группы контроля. Реабилитация проводилась на базе санатория «Светлана» (подразделение Краевой клинической больницы, г. Пермь). До и после лечения у всех детей проведены сбор жалоб и анамнеза, обследование соматического и неврологического статуса. Выраженность астении определяли по многомерной шкале усталости, функциональный статус — по шкале функционального статуса после перенесенного COVID-19, вегетативные проявления констатировали при помощи опросника и схемы А.М. Вейна. Уровень моноцитарного хемотаксического протеина 1 в слюне определяли с помощью иммуноферментного анализа.</p></sec><sec><title>Результаты</title><p>Результаты. У детей, перенесших COVID-19, констатировали повышенный уровень астении по субшкале общей слабости — 81,22 [50,0; 100,0] балла (р = 0,02 по сравнению со значением группы контроля), сопряженный с вегетативными расстройствами, и содержание моноцитарного хемотаксического протеина 1 в слюне (18,0 [12,5; 29,7] пг/мл) было выше, чем в группе контроля (16,35 [11,00; 22,60] пг/мл; р = 0,012). После реабилитационных мероприятий с использованием санаторных факторов отмечено значимое снижение выраженности астении — 87,18 [75,0; 100,0] (р = 0,02), уменьшились проявления вегетативной дисфункции и класс функционального статуса с 1,74 [1,0; 3,0] до 0,77 [0; 1,0] (р = 0,02), повысился уровень саливаторного моноцитарного хемотаксического протеина 1 до 23,1 [13,7; 43,7] пг/мл (p = 0,04). Изменение его количественного содержания сопряжено со смягчением клинических проявлений постковидного синдрома, поэтому повышение уровня данного протеина следует рассматривать как положительную динамику.</p></sec><sec><title>Заключение</title><p>Заключение. Постковидный синдром у детей школьного возраста проявляется астеническими и вегетативными расстройствами. Реабилитационные санаторные факторы оказывают благоприятное влияние на клинические проявления постострого синдрома, а также на концентрацию саливаторного моноцитарного хемотаксического протеина 1.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim. To study the effects of sanatory rehabilitation factors for the intensity of asthenic manifestations of post-COVID syndrome in school-aged children.</p></sec><sec><title>Design</title><p>Design. A non-randomized controlled study was conducted.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. We examined 60 children aged 8 to 13 years old with asthenic manifestations of post-COVID syndrome; 20 healthy children were used as controls. Rehabilitation was organised at Svetlana health camp (a branch of the Territorial Clinical Hospital, Perm). All children shared their complaints and medical history as well as had their somatic and neurological status checked before and after rehabilitation. The degree of asthenia was determined using the Multidimensional Fatigue Scale; the functional status was evaluated using the functional status scale for post-COVID-19 patients; vegetative manifestations were recorded in a questionnaire and a pattern developed by A. M. Wein. Saliva levels of monocytic chemotactic protein-1 were determined with ELISA.</p></sec><sec><title>Results</title><p>Results. Children with past COVID-19 demonstrated a higher level of asthenia seen on the fatigue sub-scale — 81.22 [50.0; 100.0] points (р = 0.02 vs. controls), together with vegetative disorders; and saliva levels of monocytic chemotactic protein-1 (18.0 [12.5; 29.7] pg/mL) were higher than in controls (16.35 [11.00; 22.60] pg/mL; р = 0.012). After rehabilitation in a health camp, the intensity of asthenia decreased to 87.18 [75.0; 100.0] (р = 0.02), vegetative dysfunction improved, and functional status class changed from 1.74 [1.0; 3.0] to 0.77 [0; 1.0] (р = 0.02); saliva levels of monocytic chemotactic protein-1 increased to 23.1 [13.7; 43.7] pg/mL (p = 0.04). Quantitative changes are associated with improved clinical manifestations of post-COVID syndrome; therefore, elevated levels of this protein are a positive change.</p></sec><sec><title>Conclusion</title><p>Conclusion. Post-COVID syndrome in school-aged children manifested with asthenic and vegetative disorders. Rehabilitation sanatory factors have favourable effect on the clinical manifestations of post-COVID syndrome, as well as the saliva concentration of monocytic chemotactic protein.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>постковидный синдром</kwd><kwd>астения</kwd><kwd>дети</kwd><kwd>моноцитарный хемотаксический протеин</kwd><kwd>реабилитация</kwd></kwd-group><kwd-group xml:lang="en"><kwd>post-Covid syndrome</kwd><kwd>asthenia</kwd><kwd>children</kwd><kwd>monocyte chemotactic protein</kwd><kwd>rehabilitation</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Vosoughi F., Makuku R., Tantuoyir M.M., Yousefi F. et al. A systematic review and meta-analysis of the epidemiological characteristics of COVID-19 in children. BMC Pediatr. 2022;22(1):613. DOI: 10.1186/s12887-022-03624-4</mixed-citation><mixed-citation xml:lang="en">Vosoughi F., Makuku R., Tantuoyir M.M., Yousefi F. et al. A systematic review and meta-analysis of the epidemiological characteristics of COVID-19 in children. BMC Pediatr. 2022;22(1):613. DOI: 10.1186/s12887-022-03624-4</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Halpin S.J., McIvor C., Whyatt G., Adams A. et al. Postdischarge symptomsand rehabilitation needsin survivors ofCOVID-19 infection: a cross-sectional evaluation. J. Med. Virol. 2021;93(2):1013–22. DOI: 10.1002/jmv.26368</mixed-citation><mixed-citation xml:lang="en">Halpin S.J., McIvor C., Whyatt G., Adams A. et al. Postdischarge symptomsand rehabilitation needsin survivors ofCOVID-19 infection: a cross-sectional evaluation. J. Med. Virol. 2021;93(2):1013–22. DOI: 10.1002/jmv.26368</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Fugazzaro S., Contri A., Esseroukh O., Kaleci S. et al. Rehabilitation interventions for Post-Acute COVID-19 syndrome: a systematic review. Int. J. Environ. Res. Public Health. 2022;19(9):5185. DOI: 10.3390/ijerph19095185</mixed-citation><mixed-citation xml:lang="en">Fugazzaro S., Contri A., Esseroukh O., Kaleci S. et al. Rehabilitation interventions for Post-Acute COVID-19 syndrome: a systematic review. Int. J. Environ. Res. Public Health. 2022;19(9):5185. DOI: 10.3390/ijerph19095185</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Groven N., Fors E.A., Stunes A.K., Reitan S.K. MCP-1 is increased in patients with CFS and FM, whilst several other immune markers are significantly lower than healthy controls. Brain Behav. Immun. Health. 2020;28(4):100067. DOI: 10.1016/j.bbih.2020.100067</mixed-citation><mixed-citation xml:lang="en">Groven N., Fors E.A., Stunes A.K., Reitan S.K. MCP-1 is increased in patients with CFS and FM, whilst several other immune markers are significantly lower than healthy controls. Brain Behav. Immun. Health. 2020;28(4):100067. DOI: 10.1016/j.bbih.2020.100067</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Sahoo O.S., Pethusamy K., Nayek A., Minocha R. et al. Paradigm of immune dysregulation in COVID-19 infection. Explor. Immunol. 2024;4: 1–33. DOI: 10.37349/ei.2024.00126</mixed-citation><mixed-citation xml:lang="en">Sahoo O.S., Pethusamy K., Nayek A., Minocha R. et al. Paradigm of immune dysregulation in COVID-19 infection. Explor. Immunol. 2024;4: 1–33. DOI: 10.37349/ei.2024.00126</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Abdullah M., Ali A., Usman M., Naz A. et al. Post COVID-19 complications and follow up biomarkers. Nanoscale Adv. 2023; 5(21):5705–16. DOI: 10.1039/d3na00342f</mixed-citation><mixed-citation xml:lang="en">Abdullah M., Ali A., Usman M., Naz A. et al. Post COVID-19 complications and follow up biomarkers. Nanoscale Adv. 2023; 5(21):5705–16. DOI: 10.1039/d3na00342f</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Kim J., Lee C.H., Park C.S., Kim B.G. et al. Plasma levels of MCP-1 and adiponectin in obstructive sleep apnea syndrome. Arch. Otolaryngol. Head Neck Surg. 2010;136(9):896–9. DOI: 10.1001/archoto.2010.142</mixed-citation><mixed-citation xml:lang="en">Kim J., Lee C.H., Park C.S., Kim B.G. et al. Plasma levels of MCP-1 and adiponectin in obstructive sleep apnea syndrome. Arch. Otolaryngol. Head Neck Surg. 2010;136(9):896–9. DOI: 10.1001/archoto.2010.142</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Nisha K.J., Suresh A., Anilkumar A., Padmanabhan S. MIP-1α and MCP-1 as salivary biomarkers in periodontal disease. Saudi Dent. J. 2018;30(4):292–8. DOI: 10.1016/j.sdentj.2018.07.002</mixed-citation><mixed-citation xml:lang="en">Nisha K.J., Suresh A., Anilkumar A., Padmanabhan S. MIP-1α and MCP-1 as salivary biomarkers in periodontal disease. Saudi Dent. J. 2018;30(4):292–8. DOI: 10.1016/j.sdentj.2018.07.002</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Yui S., Sasayama D., Yamaguchi M., Washizuka S. Altered levels of salivary cytokines in patients with major depressive disorder. Clin. Neurol. Neurosurg. 2022;221:107390. DOI: 10.1016/j.clineuro.2022.107390</mixed-citation><mixed-citation xml:lang="en">Yui S., Sasayama D., Yamaguchi M., Washizuka S. Altered levels of salivary cytokines in patients with major depressive disorder. Clin. Neurol. Neurosurg. 2022;221:107390. DOI: 10.1016/j.clineuro.2022.107390</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Колотов К.А., Распутин П.Г. Моноцитарный хемотаксический протеин-1 в физиологии и медицине. Пермский медицинский журнал. 2018;3:99–105. DOI: 10.17816/pmj35399-105</mixed-citation><mixed-citation xml:lang="en">Kolotov K.A., Rasputin P.G. Monocyte chemotactic protein-1 in physiology and medicine. Perm Medical Journal. 2018;3:99–105. (in Russian). DOI: 10.17816/pmj35399-105</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Singh S., Anshita D., Ravichandiran V. MCP-1: function, regulation, and involvement in disease. Int. Immunopharmacol. 2021;101(PtB):107598. DOI: 10.1016/j.intimp.2021.107598</mixed-citation><mixed-citation xml:lang="en">Singh S., Anshita D., Ravichandiran V. MCP-1: function, regulation, and involvement in disease. Int. Immunopharmacol. 2021;101(PtB):107598. DOI: 10.1016/j.intimp.2021.107598</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Pasrija R., Naime M. The deregulated immune reaction and cytokines release storm (CRS) in COVID-19 disease. Int. Immunopharmacol. 2021;90:107225. DOI: 10.1016/j.intimp.2020.107225</mixed-citation><mixed-citation xml:lang="en">Pasrija R., Naime M. The deregulated immune reaction and cytokines release storm (CRS) in COVID-19 disease. Int. Immunopharmacol. 2021;90:107225. DOI: 10.1016/j.intimp.2020.107225</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Chen Y., Jinglan W., Chenxi L., Su L. et al. IP-10 and MCP-1 as biomarkers predicting disease severity of COVID-19. Mol. Med. 2020;26(1):97. DOI: 10.1186/s10020-020-00230-x</mixed-citation><mixed-citation xml:lang="en">Chen Y., Jinglan W., Chenxi L., Su L. et al. IP-10 and MCP-1 as biomarkers predicting disease severity of COVID-19. Mol. Med. 2020;26(1):97. DOI: 10.1186/s10020-020-00230-x</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Huang C., Wang Y., Li X., Ren L. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223):497–506. DOI: 10.1016/S0140-6736(20)30183-5</mixed-citation><mixed-citation xml:lang="en">Huang C., Wang Y., Li X., Ren L. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223):497–506. DOI: 10.1016/S0140-6736(20)30183-5</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Behnood S.A., Shafran R., Bennett S.D., Zhang A.X.D. et al. Persistent symptoms following SARS-CoV-2 infection amongst children and young people: a meta-analysis ofcontrolled and uncontrolled studies. J. Infect. 2022;84(2):158–70. DOI: 10.1016/j.jinf.2021.11.011</mixed-citation><mixed-citation xml:lang="en">Behnood S.A., Shafran R., Bennett S.D., Zhang A.X.D. et al. Persistent symptoms following SARS-CoV-2 infection amongst children and young people: a meta-analysis ofcontrolled and uncontrolled studies. J. Infect. 2022;84(2):158–70. DOI: 10.1016/j.jinf.2021.11.011</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Spruit M.A., Holland A.E., Singh S.J., Tonia T. et al. COVID-19: interim guidance on rehabilitation in the hospital and post-hospital phase from a European Respiratory Society and American Thoracic Society-coordinated International Task Force. Eur. Respir. J. 2020;56(6):2002197. DOI: 10.1183/13993003.02197-2020</mixed-citation><mixed-citation xml:lang="en">Spruit M.A., Holland A.E., Singh S.J., Tonia T. et al. COVID-19: interim guidance on rehabilitation in the hospital and post-hospital phase from a European Respiratory Society and American Thoracic Society-coordinated International Task Force. Eur. Respir. J. 2020;56(6):2002197. DOI: 10.1183/13993003.02197-2020</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Barker-Davies R.M., O'Sullivan O., Senaratne K.P.P., Baker P. et al. The Stanford Hall consensus statement for post-COVID-19 rehabilitation. Br. J. Sports Med. 2020;54(16):949–59. DOI: 10.1136/bjsports-2020-102596</mixed-citation><mixed-citation xml:lang="en">Barker-Davies R.M., O'Sullivan O., Senaratne K.P.P., Baker P. et al. The Stanford Hall consensus statement for post-COVID-19 rehabilitation. Br. J. Sports Med. 2020;54(16):949–59. DOI: 10.1136/bjsports-2020-102596</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
